All news

AbbVie (ABBV) Receives a Buy from Cantor Fitzgerald

Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash

Cantor Fitzgerald analyst Carter Gould reiterated a Buy rating for AbbVie (ABBV) with a price target of $290.00. This positive sentiment is echoed by Piper Sandler, though Citi maintains a Hold rating. The article also notes negative insider sentiment for ABBV over the past quarter, with recent share sales by a company EVP.

Read original source

ABBV company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.